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Abstract
Background
Mutations in the filaggrin gene, an epidermal structural protein, are the strongest risk factor identified for development of atopic dermatitis. Up to 50% of patients with moderate-to-severe atopic dermatitis in European populations have filaggrin-null alleles compared with a general population frequency of 7-10%. 
Objective
This study aimed to investigate the relationship between filaggrin-null mutations and epidermal antigen-presenting cell maturation in individuals with and without atopic dermatitis. Additionally, we investigated whether the cis isomer of urocanic acid, a filaggrin breakdown product, exerts immunomodulatory effects on dendritic cells.
Methods 
Epidermal antigen presenting cells from non-lesional skin were assessed by flow cytometry (n=27) and confocal microscopy (n=16). Monocyte-derived dendritic cells from healthy volunteers were used to assess effects of cis- and trans-urocanic acid on dendritic cell phenotype by flow cytometry (n=11). 
Results 
Epidermal antigen presenting cells from filaggrin-null individuals had increased CD11c expression. Confocal microscopy confirmed this, and additionally revealed an increased number of epidermal CD83+ Langerhans cells in filaggrin-null individuals. In vitro, differentiation in the presence of cis-urocanic acid significantly reduced co-stimulatory molecule expression on monocyte-derived dendritic cells from healthy volunteers and increased their ability to induce a regulatory T cell phenotype in mixed lymphocyte reactions. 
Conclusions
We show that individuals with filaggrin-null mutations have more mature Langerhans cells in non-lesional skin whether or not they have atopic dermatitis. We also demonstrate that cis-urocanic acid reduces maturation of dendritic cells and increases their capacity to induce regulatory T cells, suggesting a novel link between filaggrin deficiency and immune dysregulation.
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Key messages
	FLG-null individuals both with and without AD have more mature Langerhans cells in their epidermis than controls
	The cis-isomer of urocanic acid, a filaggrin breakdown product, is able to downregulate co-stimulatory molecule expression of dendritic cells and increase their induction of a regulatory T cell phenotype in co-cultures in vitro 
	Relative urocanic acid deficiency in FLG-null individuals may be a mechanism for increased Langerhans cell maturation and reduced epidermal regulatory T cell populations, resulting in inflammatory skin disease

Capsule summary
Filaggrin-null mutations, the major genetic determinant of atopic dermatitis, may cause epidermal immune dysregulation through a relative deficiency of the filaggrin breakdown product, urocanic acid.
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Introduction
Mutations in the gene encoding filaggrin (FLG), an epidermal structural protein, are associated with different phenotypes: atopic dermatitis (AD); ichthyosis vulgaris (IV) or clinically normal skin. Up to 50% of patients with moderate-to-severe AD in European populations have at least one FLG-null allele (1) compared with a general population frequency of 7-10% (2). While the finding of such a robust gene association has enlivened research in to what had been considered a complex polygenic disorder, the relationship between FLG-null mutations and AD has not yet been clearly elucidated. 
The ‘outside-inside’ theory of the pathogenesis of AD proposes that a deficient skin barrier is the primary abnormality driving the disease, allowing allergens, antigens and microbial danger signals to penetrate the epidermis and activate local antigen presenting cells (APCs). Human epidermis is colonised by a specialised subset of APC known as Langerhans cells (LCs). In AD, persistent LC stimulation through a defective skin barrier may result in chronic Th2 driven atopic inflammation (3). As filaggrin is involved in collapsing keratinocytes to form the densely packed stratum corneum, it is thought to play a crucial role in maintaining physical skin barrier integrity (4;5). The outside-inside theory therefore suggests a causative link between genetic filaggrin deficiency and the development of AD. 

Filaggrin breakdown products may also be important in skin barrier function. Filaggrin is rich in histidine, which is converted in the epidermis to trans-urocanic acid (trans-UCA). This in turn is naturally converted to cis-urocanic acid (cis-UCA) in the skin on exposure to ultra-violet radiation (6). Cis-UCA has been previously investigated as a potential immunomodulator of allergic responses in the skin, and it has been shown that topical (7) or systemic (8) administration of cis-UCA suppresses skin immune responses to viral infection in mice. Given systemically to mice it induces tolerance to cutaneous allergens (9), while in humans topical application of cis-UCA blunts the cell mediated response to dinitrochlorobenzene (10). While topical cis-UCA is currently in early phase trials as a possible treatment for atopic dermatitis (11), its exact mode of action is not known.
In this study we investigated the maturation state of epidermal APCs in individuals with FLG-null mutations, looking for any differences in APC phenotype between FLG-null individuals with and without AD and any correlation with skin barrier function. We also investigated whether cis-UCA affects dendritic cell phenotype and function in vitro. 

Methods
Recruitment and characterisation of volunteers 
The study was approved by the Lothian Research Ethics Committee (07/MRE00/109) and informed written consent was obtained from all participants. Subjects were recruited from general outpatient and patch test clinics at the Department of Dermatology, Royal Infirmary of Edinburgh (AD subjects only) and medical students and staff at the University of Edinburgh and the Southern General Hospital Glasgow. Diagnosis of AD was based on the UK working party’s diagnostic criteria (12). Subjects were interviewed about personal and family history of atopy and current and past management of AD and were assessed for symptoms and signs of AD and IV by both questionnaire and examination (13). AD severity was measured using the Six Area Six Sign Atopic Dermatitis (SASSAD) severity score (14).  No subjects had used oral or topical steroids for at least one week prior to the study. Whole blood was obtained from heathy volunteers at the MRC Centre for Inflammation Research, University of Edinburgh (Ethics approval 08/S1103/38).
Genotyping 
Genotyping of subjects involved in physical skin barrier assessment and suction blister analysis by flow cytometry was performed using a TAQMAN-based allelic discrimination assay (Applied Biosystems, CA, US) for the two most common FLG mutations in European populations (2282del4 and R501X). Samples were analysed at Source Bioscience, Nottingham, UK or by The Human Genetics Unit, University of Dundee. Subjects involved in suction blister analysis by confocal microscopy were genotyped for the four most common FLG mutations in European populations (2282del4, R501X, S3247X and R2447X) at the Wellcome Trust Clinical Research Facility, Western General Hospital, Edinburgh. Probes and primers were as described previously (15).  
Suction blisters
Suction blister cups were applied to the upper inner arm to produce epidermal blisters using a suction blister device (InnoKas Medical Oy, Kempele, FI). Each cup formed up to five blisters 5mm in diameter after 90-120m at a suction pressure of 400mbar applied at 10s intervals. Suction blisters from those with AD were taken from clinically uninvolved skin. For details of the quantification of cis- and trans- urocanic acid isomers in suction blister fluid see Supplementary Methods in the Online Repository.
Measurement of Transepidermal Water Loss (TEWL)
Subjects were asked not to take anti-histamines or apply any topical treatments including emollients for 3d before the study.  All physiological measurements were taken from uninvolved flexor forearm skin (4cm below the antecubital fossa) following 10m acclimatisation to standardised conditions (20-22oC, humidity 40-60%). Measurements were performed in an open top box to limit air convection currents and condensation (16). TEWL was measured using the Tewameter TM300 (Courage and Khazaka, Cologne, DE) with an open chamber probe. Measurements were repeated three times. 
Tape-stripping 
Tape-stripping was performed using 14mm D-Squame tape-discs (CuDerm Corporation, TX, US). A cylindrical weight applying a pressure of 225g/cm2 was applied for 10s before the tapes were removed unidirectionally using forceps (17). The number of tape-strips required to abrogate the permeability barrier (TEWL >20g/m2/hour) (18) was recorded by measuring TEWL after each tape strip. 
Phenotypic analysis of epidermal antigen presenting cells
For flow cytometry, blister roofs were incubated at 37°C for 30m with 0.05% trypsin in phosphate buffered saline (PBS) before manual disaggregation. PBS containing 1% fetal calf serum (FCS) was added and the cells were washed by centrifugation (10m at 300g). The pellet was resuspended in 1ml FACS wash buffer (BD Biosciences, Oxford, UK) containing 5% mouse serum and incubated for 10m on ice, washed and resuspended in 200µl FACS wash containing 5% mouse serum. For details of antibody staining please see Supplementary Methods in the Online Repository. Samples were collected using a BD LSR Fortessa Flow cytometer (BD Biosciences).  Anti-mouse CompBead Plus (BD Biosciences) were used to calibrate colour compensation. Results were analysed using Flow-Jo™ software (Treestar, OR, US). 
For confocal microscopy, epidermal samples were fixed for 30m in 90% acetone/10% methanol and then washed in three changes of phosphate buffered saline (PBS), (Gibco, MA, US) for 10m each. Samples were incubated with antibodies for 1hr in PBS with 0.1% BSA (Sigma-Aldrich, MO, US) and then washed 3 times in PBS. For details of antibody staining panels please see Supplementary Methods in the Online Repository. Staining was done at room temperature and samples were protected from light. Samples were mounted on Superfrost Plus slides (BDH Laboratory Supplies, Dorset, UK) in Permafluor (Thermo Scientific, MA, US) and stored at 2-5°C.
Slides were observed using a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar, DE) with an x40 oil immersion objective. Image stacks were acquired in 1.01µm slices through the epidermis. Images were deconvolved using Huygens Essential Software (Scientific Volume Imaging, Hilversum, NL). Basic image analysis was performed using ImageJ software (National Institutes for Health, MD, US) and 3 dimensional (3D) image analysis was performed using Volocity 5.5 (PerkinElmer, MA, US). LC volumes were calculated using CD1a staining as a proxy measure. Individual cells were identified using an intensity threshold and 50 cell volumes were averaged to give a mean LC volume for each individual. The cell volume enclosed by CD11c cell surface expression was also calculated as above. 
Generation of monocyte derived dendritic cells (MdDC)
Peripheral blood mononuclear cells were obtained from whole blood by Ficoll gradient (Ficoll-Paque PLUS, GE Healthcare, Buckinghamshire, UK). CD14+ monocytes were isolated by positive selection using magnetic-activated cell sorting with CD14+ microbeads according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, DE). CD14+ monocytes were cultured in 12-well plates (Nunclon delta surface, Thermo Scientific) at a density of 2 x 106 cells/ml in RPMI 1640 culture medium (Gibco) buffered with 20mM HEPES, 5% human AB serum and 1% L-glutamine for 7d. The medium was supplemented with 50ng/ml GM-CSF (Peprotech, NJ, US) and 15ng/ml IL-4 (Invitrogen) and cis- or trans-urocanic acid (UCA) (Sigma-Aldrich) were added to wells at concentrations of 10 or 100µg/ml on d0. These concentrations were chosen for the in vitro experiments to best mimic physiological concentrations (19).  Fresh media supplemented with cytokines and UCA was added on d3 and d5. A portion of the immature DCs were collected on d7 for analysis; remaining cells were stimulated with LPS (1ng/ml) or LTA (10µg/ml) and harvested on d8, when MdDC viability was at least 90% in cultures with and without cis- and trans-UCA. All cultures were protected from light.
Flow cytometric analysis of monocyte-derived dendritic cells
For details of antibody staining panels please see Supplementary Methods in the Online Repository. 
MdDC and CD4 T cell co-culture
Immature MdDCs conditioned with or without 100 µg/ml cis-UCA were co-cultured with allogenic CD4 T cells stained with proliferation dye EF670 (eBioscience) at a ratio of 1:10 in 96-well plates. CD4 T cell isolation details are given in Supplementary Methods in the Online Repository.  Cells were co-cultured at 37°C in a humidified atmosphere of 5% CO2 for 5d. Anti CD3/CD28 1µg/ml (eBioscience) was added to a portion of CD4 T cells as a positive control. The proliferation of CD4 T cells and the proportion of CD4+CD25+FoxP3+CD127- cells were analysed using flow cytometry. For details of antibody staining panel please see Supplementary Methods in the Online Repository.  
Statistical analysis 
Statistical analysis was performed using PRISM™ 6 (GraphPad Software Inc, CA, US). Mann-Whitney U tests, Kruskal Wallis and Friedman tests with Dunn’s post-test comparisons were used to analyse data. Data are presented as mean + SD unless otherwise stated; p-values <0.05 were considered significant. 
Results
Subjects
264 subjects were genotyped. Of these, 117 were clinically phenotyped and participated in further studies. 77 had AD (all mild to moderate disease) of whom 56 were WT and 21 had FLG-null mutations (18 FLG+/-, 3 FLG-/-). The remaining 40 subjects had clinically normal skin; 27 were WT and 13 had FLG-null mutations (all FLG+/-). No subjects met the diagnostic criteria for IV.
Mean SASSAD scores were very similar between AD groups involved in each part of the study (Table 1). Total serum IgE (IU/ml) was measured in 78 of the 84 subjects who had TEWL and tape-stripping performed. As expected IgE levels were significantly higher in AD subjects (629.5+/-1286) compared to non-AD subjects (54+/-59.3, p<0.0001). However, FLG-status did not influence IgE levels AD in subjects (IgE WT AD subjects (678 +/-1374) versus FLG-null AD subjects (443+/- 892), p=0.62). 
Langerhans cells have higher CD11c expression in FLG-null individuals with and without AD 
27 subjects had suction blister samples analysed by flow cytometry (for gating strategy see Figure E1 in the Online Repository). Total live cell yields ranged from 5000-65000, without significant differences between groups. There was no difference in the time taken to raise blisters within the different subject groups. Proportions of HLA-DR+ CD1a+ cells were similar between the groups (2.9% – 4.3%). There was a significantly higher proportion of CD11chi cells amongst HLA-DR+ CD1a+ cells in FLG-null than in WT individuals, with the highest level in FLG-null non-AD subjects  (all FLG-null  56%+/-10.2 CD11chi cells vs all WT 34%+/-15.6, p=0.0006, see Figure 1A and 1B). 
16 subjects had suction blister samples analysed by confocal microscopy. There was no significant difference in the epidermal thickness between the different groups, as calculated by the mean number of Z stack slices required to visualise each sample (see Figure E2 in the Online Repository). All CD1a+ dendritic cells in the blister roofs were langerin positive confirming that they were all LCs (Figure 2A). The mean number of LC per mm2, the mean volume of LCs, and the mean number of dendrites per LC were similar between the groups (data not shown). Comparing all FLG-null with all WT individuals, the mean volume enclosed by CD11c staining (µm3) was significantly higher in FLG-null subjects (all FLG-null 941.2+/-690.9 µm3 vs all WT 257.5+/-324.3 µm3, p=0.04, see Fig. 2B). 
More CD83+ Langerhans cells in FLG-null individuals with and without AD 
Analysis of confocal microscopy images revealed occasional CD83+ LCs which also showed increased expression of HLA-DR (see Figure E3 in the Online Repository). Compared with all WT individuals, the number of CD83+ LC was significantly higher in FLG-null subjects (all FLG-null 2.23+/-1.2 CD83+ LC per 100 LC vs all WT 0.75+/-0.4, p=0.01, see Figure 2C). There were no significant differences in the mean volume enclosed by HLA-DR staining between groups (data not shown).
FLG status only affects barrier function in AD
Resting TEWL (g/m2/hr) was measured in 84 subjects, and number of tape-strips required to reach TEWL >20 g/m2/hr was measured in 82 subjects. TEWL was significantly higher in the FLG-null AD group than in WT AD individuals (FLG-null AD 8.7g/m2/hr+/-1.9 vs WT AD 8.1g/m2/hr+/-5.6, p=0.02, see Figure 3A). Two WT AD subjects with very high resting TEWL >2SD from the mean were identified as statistical outliers using a ROUT test (Q=0.2%). When these individuals were excluded from the analysis, the mean TEWL in the WT AD group was 7.1g/m2/hr+/-2.3 (p=0.007, FLG-null AD vs WT AD). The number of tape-strips required to reach TEWL>20g/m2/hr per hour was significantly lower in the FLG-null AD group compared to all other groups (FLG-null AD 11.25+/-2 strips vs WT AD 14.7+/-4.9 strips vs FLG-null non-AD 17.00+/-3.9 strips vs WT non-AD 18.9+/-5.9 strips, p=0.0001, see Figure 3B). Interestingly, non-AD individuals with and without FLG-null mutations required a similar number of tape-strips to reduce the permeability barrier.
Cis-UCA reduces co-stimulatory molecule expression in MdDCs
Although immature MdDCs at d7 had only a low level of expression of HLA-DR and co-stimulatory molecules (see Table E1 and Figure E5 in the Online Repository), cells conditioned with 100µg/ml cis-UCA showed reduced expression of CD86, PDL-1, HLA-DR and CD40 compared to control (CD86 MFI 3813+/-1414 vs 6275+/-2086 p<0.0001; PDL-1 MFI 96+/-44 vs 149+/-88 p<0.0001; HLA-DR MFI 863+/-549 vs 1112+/-627 p=0.001; CD40 MFI 507+/-378 vs 708+/-477 p=0.0001, see Figure 4 A-D), while conditioning with trans-UCA had no effect on expression of these molecules. The expression of CD1a and CD11c did not change with cis-UCA conditioning (data not shown).
MdDC stimulation with LPS or LTA on d7 increased HLA-DR and co-stimulatory molecule expression on d8, as expected (see Table EI in the Online Repository). LPS-stimulated MdDC conditioned with cis-UCA, but not trans-UCA, had significantly reduced expression of CD86 and PDL-1 compared to control on d8 (CD86 MFI 12541+/-4136 vs 15490+/-5150, p=0.04;  PDL-1 MFI 256+/-118 vs 408+/-204, p=0.02, see Figure 5 A, B).  There were no significant changes in the expression of HLA-DR, CD40, CD1a or CD11c (data not shown). MdDC stimulated with LTA showed a similar pattern of responses as LPS stimulated cells (data not shown). Cells harvested at d9 showed similar results to those harvested on d7 or d8 indicating that cis-UCA did not simply delay maturation (data not shown). 
Cis-UCA conditioned mdDCs induce regulatory T cells in co-culture 
Cis-UCA conditioned immature MdDCs did not affect proliferation of CD4 T cells at d5 compared to control (see Figure 6 A). However, CD4 T cells co-cultured with cis-UCA conditioned MdDCs showed a higher proportion of CD25+Foxp3+CD127- cells at d5 than those cultured with trans-UCA conditioned MdDCs (see Figure 6 B-D). This effect was not observed in CD4 T cells co-cultured with cis-UCA conditioned LPS-stimulated MdDCs (data not shown).
Discussion
While phenotypically different subsets of APCs have been identified in lesional AD skin, Langerhans cells (LC) are thought to be the only APCs found in non-lesional epidermis (20;21). For many years the classic paradigm of LC function was of antigen uptake and processing in the epidermis followed by maturation and migration to skin draining lymph nodes for antigen presentation to T cells (22).  This concept has recently been challenged by the observations that the majority of cutaneous lymphocyte antigen positive T cells are present in skin and that LCs can evoke both tolerogenic and immunogenic T cell responses (23).

The ‘outside-inside’ theory of AD pathogenesis proposes that epidermal APCs in AD individuals will be exposed to more ‘danger signals’ through a deficient skin barrier, leading to APC maturation and T cell driven inflammatory skin disease. Using confocal microscopy, we confirmed that all CD1a+, HLA-DR+ epidermal cells from suction blister roof samples express langerin, verifying that they are Langerhans cells. While they are present in similar numbers, are of similar size and have a similar number of dendrites per cell in each subject group, we demonstrate that LC from FLG-null individuals both with and without AD have higher CD11c and CD83 expression than those of controls. 

CD11c is a member of the CD18 integrin family and is expressed at a high level on most dendritic cells (24) but only at a low level by LCs (25). It has previously been noted that some individuals have LCs expressing higher levels of CD11c, in combination with increased expression of HLA-DR(26). CD11c expression has been shown to be upregulated in human LC treated with retinoic acid, and in the same experiment it was shown that a blocking antibody to CD11c was able to completely abrogate the ability of the LCs to present alloantigen to T cells, suggesting a critical role in antigen presentation(27). A recent study using confocal microscopy to observe the interaction between LCs and tight junctions in AD also found occasional LCs with higher expression of HLA-DR which they considered to be activated LCs(28).  CD83 is a well characterised marker of dendritic cell activation which is expressed on mature LCs and may be involved in T cell activation(29;30). The upregulation of these molecules suggests that in non-lesional skin, FLG-null individuals have more activated LCs, compared to WT individuals. 

In response to these findings, we investigated whether FLG-null individuals had a measurably deficient skin barrier which could explain LC activation by increased exposure to danger signals. We found that FLG-null subjects with AD had a higher resting TEWL at baseline and required significantly fewer tape-strips to increase TEWL to >20g/m2/hr compared to WT AD (and control) indicating an intrinsic upper epidermal fragility. These findings are in agreement with a recent study which used a similar tape-stripping method(31).  Interestingly, however, not only did FLG-null subjects with normal skin show no difference in resting TEWL at baseline compared to control, but on physically challenging the epidermal barrier by tape-stripping, they were again no different to controls. This implies that more than a genetic deficiency in filaggrin is required to produce a functionally deficient skin barrier. 

To investigate why FLG-null individuals with physically normal appearing skin could have more mature epidermal LCs, we studied the effects of the filaggrin breakdown product, cis-UCA,  on MdDCs. Concentrations of UCA in human skin – as measured by epidermal tape-stripping - are known to vary widely between individuals, ranging from 2-62 nmol/cm-2 (equivalent to 40-1230µg ml-1)(19). A maximum of 60-70% of the total UCA concentration can be in the cis isomer at any time, depending on recent UVR exposure(32), and both cis and trans-UCA are able to diffuse into the subepidermal compartment (32-35) (for more details see Online Repository). 

 We demonstrate that cis-UCA, but not trans-UCA, is able to downregulate the expression of CD86, HLA-DR, CD40 and PDL-1 on immature MdDCs and the expression of CD86 and PDL-1 on LPS-matured MdDCs. Our finding that immature MdDCs conditioned with cis-UCA induce a higher proportion of CD4 T cells with a Treg phenotype in co-culture is in agreement with a previously published study (36). If cis-UCA is able to exert a similar effect on LCs – which are regarded as immature DCs - in vivo this suggests a potential role in maintaining tolerance in the epidermis by preventing LCs from providing immunogenic signals to skin-resident T cells and by increasing their ability to induce a local Treg cell phenotype. Additionally, as cis-UCA levels are increased by UVR this is also potentially a mechanism for UVR induced immunosuppression. A reduced level of cis-UCA, as would be expected in individuals with FLG-null mutations, could therefore result in the LC maturation we observed in the epidermal suction blister samples. 

While we did not identify significant differences in levels of cis-UCA in suction blister fluid between the groups (see Figure E4 in Online Repository) a statistically significant step-wise decrease in total epidermal UCA levels from normal controls to WT AD subjects, FLG-null heterozygotes with AD, and finally FLG-null homozygotes with AD has been reported based on a tape-stripping method to determine UCA levels in the epidermis (37). Within AD subjects, FLG genotype was the major determinant of UCA levels, with disease severity as a secondary modifier (37).   

Our data does not address why some individuals with FLG-null mutations develop AD, while others maintain a normal clinical phenotype. If both groups of individuals have activated LC in their epidermis, potentially providing activating signals to skin-resident T cells, it would suggest that there are overriding tolerogenic mechanisms in those who do not develop skin inflammation. 
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Tables
Table I. Clinical assessment of genotyped subjects 
TEWL and Tape Stripping Group
	WT non-AD	WT AD	FLG non-AD	FLG AD
n	18	46	8	12
Age (range)	28 (19-59)	35 (18-76)	28 (19-58)	35 (22-57)
Male: female	8:10	16:30	4:4	5:7
SASSAD +/- SD	n/a	11 +/- 9.3	n/a	12 +/- 7.5
IgE +/- SD*	63 +/- 63(n=14)	678 +/- 1374(n=46)	33 +/- 47(n=6)	443 +/- 892(n=12)
Asthma	2 (11%)	15 (33%)	2 (25%)	5 (42%)
Hay fever‡	1 (6%)	27 (59%)	1 (13%)	4 (33%)
Suction blister flow cytometry Group
	WT non-AD	WT AD	FLG non-AD	FLG AD
n	8	7	4	8
Age (range)	31 (20-55)	42 (27-76)	21 (19-25)	37 (27-57)
Male: female	3:5	3:4	3:1	3:5
SASSAD +/- SD	n/a	6 +/- 4	n/a	8 +/- 3
Suction blister immunostaining Group
	WT non-AD	WT AD	FLG non-AD	FLG AD
n	4	3	5	4
Age (range)	34 (21-51)	21 (20-21)	35 (20-54)	40 (22-56)
Male: female	3:1	2:1	4:1	2:2
SASSAD +/- SD	n/a	12 +/- 8	n/a	15 +/- 8
*AD vs non-AD p=0.0001, ‡AD vs non-AD p=0.0001

Figure legends
Figure 1: FLG-null individuals with and without AD have a higher proportion of CD11chi epidermal antigen presenting cells than wild type individuals
(A) Scatter plot comparing the percentage of CD11chi cells among the different subject groups. Kruskal Wallis test p=0.009, Dunn’s multiple comparison post-test p values shown on graph, *=p<0.05. (B) Scatter plot comparing the percentage of CD11chi cells in all WT subjects vs all FLG-null subjects, p value calculated by Mann-Whitney test shown on graph.
Figure 2: Confocal microscopy confirms increased CD11c expression in Langerhans cells in FLG-null individuals with and without AD
 (A) CD1a+ (red) and langerin (white) (B) Scatter plot comparing the mean volume of CD11c staining per LC in all WT subjects vs all FLG-null subjects, p value calculated by Mann-Whitney test. (C) Scatter plot comparing the mean number of CD83+ LC per 100 LC in all WT subjects vs all FLG-null subjects, p value calculated by Mann-Whitney test. 
Figure 3: Skin barrier function is reduced in FLG null individuals with but not without AD 
(A) Comparison of mean resting TEWL in all subject groups. FLG-null AD vs WT AD p= 0.02, Mann-Whitney test. Lines show minimum to maximum values. (B) Plot showing number of tapestrips required to reach TEWL>20g/hr/m2 in all subject groups. Kruskal Wallis test p=<0.0001, Dunn’s multiple comparison post-test values shown on graph, ****=p<0.0001, *=p<0.05, lines show minimum to maximum values. 

Figure 4: Cis-UCA reduces co-stimulatory molecule expression in unstimulated MdDCMdDCs were cultured for 7d in the presence of cis-UCA (c-UCA) or trans-UCA (t-UCA). Culture with 100µg/ml cis-UCA caused a significant reduction in MFI of (A) CD86 (B) PDL-1 (C) HLA-DR and (D) CD40. Statistical analysis by repeated measures ANOVA (Friedman test with Dunn’s multiple comparison post-test) ***=p<0.001; **=p<0.01, lines show median and interquartile range.
Figure 5: Cis-UCA reduces co-stimulatory molecule expression in LPS stimulated MdDC
MdDCs cultured for 7d in the presence of cis-UCA (c-UCA) or trans-UCA (t-UCA) were stimulated with 1ng/ml LPS for 24 hours. Conditioning with 100µg/ml cis-UCA caused a significant reduction in MFI of (A) CD86 and (B) PDL-1. Statistical analysis by repeated measures ANOVA (Friedman test with Dunn’s multiple comparison post-test) **=p<0.01,*=p<0.05, lines show median and interquartile range.
Figure 6: Cis-UCA conditioned MdDCs induce more cells with a Treg phenotype
(A) Proliferation of CD4 T cells in co-culture (B) Induction of cells with T reg phenotype after co-culture. Kruskal Wallis test with Dunn’s multiple comparison post-test, ns=not significant, *=p<0.05 (C) Similar proportion of CD25+ cells after co-culture with trans and cis-UCA conditioned MdDCs (D) More CD25+FoxP3+CD127- cells after co-culture with cis-UCA conditioned MdDCs (A,C,D–representative plots from one donor shown).
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